We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Structural Studies Reveal Molecular Basis for Bacterial Motility in the Urinary Tract

By LabMedica International staff writers
Posted on 23 Mar 2016
A team of molecular microbiologists has unraveled the mechanism used by Escherichia coli bacteria to bind to cells lining the urinary tract and explained how the pathogen migrates to the bladder despite the strong force of urine flowing in the other direction. More...


E. coli attaches to host epithelia via the fimbrial adhesion FimH, a two-domain protein at the tip of type I pili recognizing terminal mannoses on epithelial glycoproteins.

Investigators at the University of Basel (Switzerland) and ETH Zurich (Switzerland) established a model system for fimbrial FimH function. A fimbril is a proteinaceous appendage in many gram-negative bacteria that is thinner and shorter than a flagellum.

The investigators revealed, in a paper published in the March 7, 2016, online edition of the journal Nature Communications, a three-state mechanism of FimH catch-bond formation based on crystal structures of all states, kinetic analysis of ligand interaction, and molecular dynamics simulations. They found that FimH bound to sugar structures on the cell surface increasingly tightly the more it was pulled. As strong tensile forces developed during urination, FimH protected the bacteria from being flushed out. In the absence of tensile force, the FimH pilin domain allosterically accelerated spontaneous ligand dissociation from the FimH lectin domain by 100,000-fold, resulting in weak affinity and allowing the bacteria to release from the cell surface and migrate in the direction of the bladder.

“Through the combination of several biophysical and biochemical methods, we have been able to elucidate the binding behavior of FimH in more detail than ever before”, said senior author Dr. Rudolf Glockshuber, professor of molecular biology and biophysics at ETH Zurich. “The protein FimH is composed of two parts, of which the second non-sugar binding part regulates how tightly the first part binds to the sugar molecule. When the force of the urine stream pulls apart the two protein domains, the sugar binding site snaps shut. However, when the tensile force subsides, the binding pocket reopens. Now the bacteria can detach and swim upstream the urethra.”

Related Links:
University of Basel
ETH Zurich



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.